EA200600477A1 - Пептиды и соединения, которые связываются с рецептором - Google Patents

Пептиды и соединения, которые связываются с рецептором

Info

Publication number
EA200600477A1
EA200600477A1 EA200600477A EA200600477A EA200600477A1 EA 200600477 A1 EA200600477 A1 EA 200600477A1 EA 200600477 A EA200600477 A EA 200600477A EA 200600477 A EA200600477 A EA 200600477A EA 200600477 A1 EA200600477 A1 EA 200600477A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptides
receptor
associate
connections
tpo
Prior art date
Application number
EA200600477A
Other languages
English (en)
Other versions
EA009286B1 (ru
Inventor
Брайан Р. Макдональд
Джеффери Кеннет Вейс
Эдвард Джон Юрков
Original Assignee
Орто-Макнейл Фармасьютикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200600477(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Орто-Макнейл Фармасьютикал, Инк. filed Critical Орто-Макнейл Фармасьютикал, Инк.
Publication of EA200600477A1 publication Critical patent/EA200600477A1/ru
Publication of EA009286B1 publication Critical patent/EA009286B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)

Abstract

Пептиды и соединения, которые связываются с рецептором тромбопоэтина (с-mpl или TPO-R) и активируют его или каким-либо иным образом действуют как агонисты ТРО.
EA200600477A 2003-08-28 2004-08-13 Пептиды и соединения, которые связываются с рецептором EA009286B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49874003P 2003-08-28 2003-08-28
PCT/US2004/026422 WO2005023834A2 (en) 2003-08-28 2004-08-13 Peptides and compounds that bind to thrombopoietin receptors

Publications (2)

Publication Number Publication Date
EA200600477A1 true EA200600477A1 (ru) 2007-02-27
EA009286B1 EA009286B1 (ru) 2007-12-28

Family

ID=34272720

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600477A EA009286B1 (ru) 2003-08-28 2004-08-13 Пептиды и соединения, которые связываются с рецептором

Country Status (33)

Country Link
US (1) US7576056B2 (ru)
EP (1) EP1675606B1 (ru)
JP (1) JP4848277B2 (ru)
KR (2) KR20120078742A (ru)
CN (2) CN1871022B (ru)
AR (1) AR045530A1 (ru)
AU (1) AU2004270656B2 (ru)
BR (1) BRPI0414008B8 (ru)
CA (1) CA2537421C (ru)
CY (1) CY1118965T1 (ru)
DK (1) DK1675606T3 (ru)
EA (1) EA009286B1 (ru)
EC (1) ECSP066396A (ru)
ES (1) ES2626107T3 (ru)
HK (1) HK1096873A1 (ru)
HR (1) HRP20170810T1 (ru)
HU (1) HUE032370T2 (ru)
IL (1) IL173965A (ru)
IS (1) IS8300A (ru)
LT (1) LT1675606T (ru)
ME (1) ME00313B (ru)
MX (1) MXPA06002292A (ru)
NO (1) NO344233B1 (ru)
NZ (1) NZ545455A (ru)
PL (1) PL1675606T3 (ru)
PT (1) PT1675606T (ru)
RS (2) RS20060141A (ru)
SG (1) SG131110A1 (ru)
SI (1) SI1675606T1 (ru)
TW (1) TWI348375B (ru)
UA (1) UA82710C2 (ru)
WO (1) WO2005023834A2 (ru)
ZA (1) ZA200602495B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
RS51237B (sr) 1998-10-23 2010-12-31 Kirin Amgen Inc. Trombopoietska jedinjenja
NZ566812A (en) * 2002-09-18 2009-07-31 Ortho Mcneil Pharm Inc Methods of increasing platelet and hematopoietic stem cell production
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
NZ545455A (en) 2003-08-28 2009-02-28 Ortho Mcneil Pharm Inc Peptides and compounds that bind to thrombopoietin receptors
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
CA2635498A1 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
CN101374540B (zh) * 2006-02-14 2013-03-06 詹森药业有限公司 Tpo肽化合物和药物组合物在治疗贫血中的用途
TWI458488B (zh) * 2006-02-14 2014-11-01 Janssen Pharmaceutica Nv Ｔｐｏ胜肽化合物及醫藥組成物於治療貧血之用途
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
WO2009148954A2 (en) * 2008-06-03 2009-12-10 Janssen Pharmaceutica Nv Dosing regimen
JP5709113B2 (ja) 2011-06-23 2015-04-30 株式会社島津製作所 分岐型両親媒性ブロックポリマー、それを用いた分子集合体及び薬剤搬送システム
CA3070442A1 (en) 2017-07-26 2019-01-31 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
WO2020154585A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
MX2021008928A (es) * 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Métodos para mejorar la protección contra lesiones vasculares y de organos, la recuperación hematopoyética y la supervivencia en respuesta a la radiacion corporal total/exposicion química.
CA3127378A1 (en) 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
US20230104658A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica Nv Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) * 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
EP0644771B2 (en) 1992-06-11 2006-12-06 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
JP3401005B2 (ja) * 1992-12-11 2003-04-28 ユニバーシティ オブ フロリダ 有害生物の防除のための材料および方法
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SG47030A1 (en) 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
KR100289201B1 (ko) 1994-02-14 2001-05-02 엘. 데이예를 카렌. 조혈 단백질과 그것의 제조를 위한 재료 및 방법
AU1843595A (en) 1994-02-14 1995-08-29 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
EP0668352A1 (en) 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
CN1229385C (zh) 1994-03-31 2005-11-30 安姆根有限公司 刺激巨核细胞生长和分化的组合物及方法
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
DE69515465T2 (de) * 1994-11-04 2000-08-03 Santen Pharmaceutical Co., Ltd Neue hydroxy-substituierte 1,3-dialkyl-harnstoffderivate
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
WO1996017062A1 (en) 1994-11-30 1996-06-06 Zymogenetics, Inc. Low molecular weight thrombopoietin
DE69636714T2 (de) 1995-04-26 2007-10-18 Kyowa Hakko Kogyo Co., Ltd. G-CSF TPO Fusionsproteine
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
TR199701526T1 (xx) * 1995-06-07 1998-03-21 Glaxo Group Limited Bir trombopoietin resept�r�ne ba�lanan peptitler ve bile�ikler.
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6060052A (en) * 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6552008B1 (en) 1999-09-24 2003-04-22 Smithkline Beecham Corporation Thrombopoietin mimetics
CZ299141B6 (cs) * 2000-12-22 2008-04-30 Ipsen Manufacturing Ireland Limited Zpusob syntézy peptidu LHRH
WO2002078612A2 (en) 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
NZ566812A (en) * 2002-09-18 2009-07-31 Ortho Mcneil Pharm Inc Methods of increasing platelet and hematopoietic stem cell production
NZ545455A (en) 2003-08-28 2009-02-28 Ortho Mcneil Pharm Inc Peptides and compounds that bind to thrombopoietin receptors

Also Published As

Publication number Publication date
CN1871022A (zh) 2006-11-29
ECSP066396A (es) 2006-08-30
CA2537421C (en) 2011-09-27
CA2537421A1 (en) 2005-03-17
TW200517103A (en) 2005-06-01
BRPI0414008B8 (pt) 2021-05-25
TWI348375B (en) 2011-09-11
EP1675606B1 (en) 2017-04-05
HK1096873A1 (en) 2007-06-15
UA82710C2 (ru) 2008-05-12
HRP20170810T1 (hr) 2017-08-11
MEP48508A (en) 2011-02-10
IL173965A0 (en) 2006-07-05
ES2626107T3 (es) 2017-07-24
KR20070017942A (ko) 2007-02-13
KR101183875B1 (ko) 2012-09-27
IL173965A (en) 2015-10-29
NO20061346L (no) 2006-05-22
WO2005023834A3 (en) 2005-05-06
JP2007504132A (ja) 2007-03-01
NZ545455A (en) 2009-02-28
CN102241742A (zh) 2011-11-16
PT1675606T (pt) 2017-05-22
BRPI0414008A (pt) 2006-10-24
PL1675606T3 (pl) 2017-08-31
BRPI0414008B1 (pt) 2018-05-15
SG131110A1 (en) 2007-04-26
CN1871022B (zh) 2011-07-06
ZA200602495B (en) 2007-06-27
AU2004270656B2 (en) 2011-03-10
RS56387B1 (sr) 2017-12-29
RS20060141A (en) 2008-08-07
CN102241742B (zh) 2014-04-02
WO2005023834A2 (en) 2005-03-17
MXPA06002292A (es) 2006-09-04
US7576056B2 (en) 2009-08-18
EA009286B1 (ru) 2007-12-28
SI1675606T1 (sl) 2017-07-31
EP1675606A2 (en) 2006-07-05
AR045530A1 (es) 2005-11-02
KR20120078742A (ko) 2012-07-10
IS8300A (is) 2006-02-14
JP4848277B2 (ja) 2011-12-28
LT1675606T (lt) 2017-11-10
US20050137133A1 (en) 2005-06-23
CY1118965T1 (el) 2018-01-10
HUE032370T2 (en) 2017-09-28
NO344233B1 (no) 2019-10-14
DK1675606T3 (en) 2017-06-19
EP1675606A4 (en) 2009-09-30
AU2004270656A1 (en) 2005-03-17
ME00313B (me) 2011-05-10

Similar Documents

Publication Publication Date Title
EA200800535A1 (ru) Пептиды и соединения, которые связываются с рецептором
EA200600477A1 (ru) Пептиды и соединения, которые связываются с рецептором
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
EA200701918A1 (ru) Белок липокалин
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
DE602005010109D1 (de) 1,1a,5,5a-tetrahydro-3-thia-cyclopropaäaüpentaleneptor-agonisten
DK1885746T3 (da) Sammensætninger relateret til opløselige G-protein-koblede receptorer (sGPCRs)
CO5720212A1 (es) Composicion de anticuerpo her2
TW200732349A (en) Anti-OX40L antibodies and methods using same
DK3085783T3 (da) Bispecifikt antistof som substitution for funktionelle proteiner
EP2284180A3 (en) Peptides that specifically bind HGF receptor (CMET) and uses thereof
MX2008000230A (es) Proteinas de enlace il-6.
EA200601759A1 (ru) Композиции рамиприла
EA200702193A1 (ru) Гликозилирование белков
AU301493S (en) Reciprocating saw
EA200701892A1 (ru) Композиции, содержащие связанную воду и компоненты, помещённые в водочувствительную основу
EA200800820A1 (ru) Композиция с замедленным высвобождением и ее применение
AU301497S (en) Reciprocating saw
EA200400393A1 (ru) Антитела против каспазы-8, их получение и применение
RU2006107412A (ru) 2,4,6-трифенил-4н-селенопиран-средство для лечения и профилактики отравлений соединениями мышьяка
HN2002000177A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso.
TR200103671U (tr) Mangal kömürünün tutuşturulması için taşıma kabı
RU2003136112A (ru) Акарицид